The use of non-invasive diagnostic imaging has evolved and fewer such tests are being performed, so it’s not to blame for rising Medicare costs, according to a new study.
It may be popular to blame non-invasive diagnostic imaging for rising Medicare costs, but a study published today in the Journal of the American College of Radiology shows that this is not true.
Medical imaging costs did peak in 2006, acknowledged David C. Levin, MD, lead author of the study. However, as its use evolved and refined, fewer such tests are being performed, lowering the expense.
According to the study findings, Medicare Part B spending for non-diagnostic imaging rose from $5.92 billion in 2000 to $11.91 billion in 2006, the peak of its use. Because providers became more aware of when to order which scans and the effects of the emitting radiation, use dropped, reducing the cost to $9.45 billion in 2010.
Similar drops were seen in other physician payments. In 2000, the cost was $1.06 billion and in 2006, the costs peaked at $2.38. By 2010, they had dropped to $1.96 billion.
“This study confirms that medical imaging costs are down significantly in recent years and runs counter to the misconceptions that imaging scans serve a primary role in rising medical costs,” said Levin. “This study should provide lawmakers and regulators with more current information on which to base medical imaging policies and allow them to correctly focus on other areas of medicine that may be seeing rising costs.”
Strategies to Reduce Disparities in Interventional Radiology Care
March 19th 2025In order to help address the geographic, racial, and socioeconomic barriers that limit patient access to interventional radiology (IR) care, these authors recommend a variety of measures ranging from increased patient and physician awareness of IR to mobile IR clinics and improved understanding of social determinants of health.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Study Explores Impact of Insurance on Treatment and Referrals for Patients with Uterine Fibroids
February 19th 2025Women with uterine fibroids and Medicaid coverage are significantly more likely to be treated with uterine artery embolization than those with commercial insurance, according to newly published research.